Ratiopharm up for grabs
This article was originally published in The Tan Sheet
Executive Summary
The Merckle Group, the parent of German OTC and generic drug firm Ratiopharm, agrees with investors at VEM VV GmbH to arrange for a bridge loan from Merckle's creditor banks in order to sell Ratiopharm. The Jan. 7 decision follows the suicide of Merckle Group founder, Adolf Merckle, which was linked to his and the company's financial crises. The sale likely will take several months, Ratiopharm says
You may also be interested in...
US FDA Needs Plan For Addressing Inspection Backlog Post-COVID, GAO Says
Agency must plan to ensure that a growing backlog of surveillance inspections does not impede its ability to conduct inspections at high-risk sites, GAO official says.
Health And Wellness Trademark Review 2 March, 2021
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
In Order Shutting Down New York Supplement Firm, Federal Judge Also Criticizes FDA’s Calculations
Judge ordering permanent injunction against Confidence USA on a complaint filed in 2019 questioned FDA's calculations for requiring the firm to recall and destroy all products it had distributed since February 2018.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: